Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tongxinluo Capsule for Restenosis After Arterial Stenting
NCT06112028Phase 4Not yet recruiting
- Start
- Oct 2023
- Primary completion
- Nov 2025
- Modality
- Small Molecules
01
Overview
Phase 4, randomised, open-label trial of Tongxinluo in in-stent restenosis (ISR) (2 arms). Primary endpoint: Changes of vascular stenosis rate after intracranial and extracranial arterial stenting at 12 months. Planned start Oct 2023; status: not yet recruiting.
02
Drugs
Tongxinluo
03
Conditions
in-stent restenosis (ISR)
Beyond the preview
Go deeper on NCT06112028.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06112028.